Teva is Now Mylan's Eighth Largest Investor as Takeover Plans Persist

Jun 12, 2015


Teva Pharmaceutical raised its stake in Mylan above 3 percent, a milestone that, according to Dutch corporate law, gives it power to submit agenda items at shareholders’ meetings.

According to Bloomberg, this move ranks Teva as Mylan’s eighth-largest investor as the Israeli drugmaker continues its push to by its rival Mylan for a current price of $40.1 billion in cash and stock.

In April, Mylan put an arcane legal structure known as a "stichting" in place. According to the WSJ, stichtings are often used as a defense against hostile takeovers, similar to a U.S. poison pill. A company sets up a stichting and gives it the option to acquire preferred shares with voting rights equal to half of all outstanding shares of common stock in the case of a hostile bid.

Teva insists that its acquisition of Mylan's shares are within the Dutch law. Teva's next key goal will be to accumulate a 4.6 percent stake, which will allow it to initiate inquiry proceedings before the Dutch Enterprise Chamber.

Read the Bloomberg article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments